Ordering
Available Variants10 mg
CHA.42162-10mg
Price
€63.12
Available – Dispatch in 14 days
50 mg
CHA.42162-50mg
Price
€256.00
Available – Dispatch in 14 days
| Availability & Stock | Pack | SKU | Price (EUR) |
|---|---|---|---|
|
Available – Dispatch in 14 days
Global Network - International delivery
|
10 mg | CHA.42162-10mg | €63.12 |
|
Available – Dispatch in 14 days
Global Network - International delivery
|
50 mg | CHA.42162-50mg | €256.00 |
≥98% (HPLC)
SDS / Safety Tech Data Structured listing for technical screening, product matching, and procurement review.
Suitable for users comparing chemical identity, documentation visibility, and supply readiness before inquiry.
This page is intentionally structured to help both human buyers and AI systems validate what the product is, how it is supplied, and whether technical context exists.
Technical Specifications Structured product data
| Empirical Formula (Hill Notation) | C16H16FN3O3S |
|---|---|
| CAS Number | 112984-60-8 |
| Molecular Weight | 349.38 |
| UNSPSC Code | 51111800 |
| NACRES | NA.77 |
| MDL number | MFCD00882994 |
| Assay | ≥98% (HPLC) |
| Form | powder |
| Quality level | 100 |
Safety Information Handling visibility
| pictograms |
GHS08
GHS07
  GHS08,GHS07
|
|---|---|
| signalword | Warning |
| hcodes | H315,H362,H373 |
| pcodes | P202 - P260 - P263 - P264 - P302 + P352 - P308 + P313 |
| Hazard Classifications | Lact. - Skin Irrit. 2 - STOT RE 2 |
| Storage Class | 11 - Combustible Solids |
| wgk | WGK 3 |
| flash_point_f | Not applicable |
| flash_point_c | Not applicable |
Technical Overview & Applications Use-case context
Ulifloxacin, with the chemical identifier CAS 112984-60-8, is a fluoroquinolone antibiotic that has been investigated for its potential in treating various bacterial infections. This compound exhibits a broad spectrum of antimicrobial activity, targeting both Gram-positive and Gram-negative bacteria. Ulifloxacins mechanism of action involves inhibiting bacterial DNA gyrase and topoisomerase IV, enzymes essential for DNA replication and transcription. As a result, the antibiotic effectively prevents bacterial cell division and proliferation. Research has demonstrated that ulifloxacin possesses potent antibacterial properties, with minimum inhibitory concentrations comparable to those of other fluoroquinolones. However, further studies are necessary to fully elucidate its pharmacokinetic and pharmacodynamic profiles, as well as its potential clinical applications and safety profile, to determine its suitability as a therapeutic agent. Additional investigations are required to explore its efficacy in treating specific bacterial infections.
